NF1 and hepatocellular carcinoma: This problem was recently addressed using CRISPR/Cas9 library screening, which identified two key resistance genes, neurofibromin 1(NF1) and dual-specificity phosphatase 9 (DUSP9), as critical drivers of lenvatinib resistance in HCC [145].